Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...
FDA Approves New Tablet Form of Evrysdi for Treatment of Spinal Muscular Atrophy
About Evrysdi Evrysdi is an SMN2-splicing modifier designed to increase functional SMN protein production. With the introduction of a new tablet formulation, Evrysdi now offers an alternative ...
Galesburg Fire Department ranks #2 in state for Fill the Boot fundraiser
The Galesburg Fire Department (GFD) really came through for people with neuromuscular diseases at the annual Fill the Boot ...
pharmaphorum2d
Abcuro raises $200m to take muscle disease drug to market
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
Benitec presents new gene therapy data at MD conference
HAYWARD, Calif. - Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company with a market capitalization of $225 million, announced today that it will present interim data from its ...
Medscape17d
Association of Duchenne Muscular Dystrophy With Autism Spectrum Disorder
006). We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder. Further work might elucidate the level of association between these two ...
TMCnet18h
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
On March 18 th Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will be giving an oral presentation in the first session dedicated to OPMD at the 2025 Muscular ...
Fierce Pharma2d
Roche scores FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...